影响MVP方案治疗晚期非小细胞肺癌疗效的因素分析  

Predictive Factors of Response to MVP Regimen in Patients with Advanced Non-small Cell Lung Cancer

作　　者：李曙光[1] 黎莉[1] 李明[1] 王秀问[1] 

机构地区：[1]山东大学齐鲁医院,山东济南250014

出　　处：《肿瘤学杂志》2002年第6期338-339,共2页Journal of Chinese Oncology

摘　　要：[目的]探讨可预测MVP方案 (丝裂霉素、长春酰胺、顺铂 )治疗晚期非小细胞肺癌 (NSCLC)疗效的指标。[方法]用MVP方案治疗晚期NSCLC96例 ,回顾性分析了影响化疗疗效的因素。[结果]KPS≥80分、初治、腺癌、单一部位转移、无骨骼转移、无贫血患者的有效率分别是43.9% ,42.5% ,40.6% ,44.4% ,37.5 % ,42.1% ,明显高于KPS60～70分、复治、鳞癌、两个以上部位转移、有骨骼转移以及贫血患者。[结论]一般状况、既往治疗、组织学类型、转移部位数目以及有无骨骼转移、贫血可作为预测MVP方案疗效的指标。To identify pretreatment variables predicting response to MVP regimen mitomycin,vindesin,cisplatin for advanced non_small cell lung cancer (NSCLC). A total of 96 evaluable patients with advanced NSCLC received MVP regimen. The relationship of pretreatment variables and response was evaluated retrospectively. KPS≥80,initial treatment,adenocarcinoma,single metastasis, no bone metastase and normal hemoglobin were associated with increased response rates.The response rates were 43.9%,42.5%,40.6%,38.2%,40.9%,42.1%,respectively.[Conclusion]Performance status,previous chemotherapy,histopathological type,the number of metastatic sites,bone metastasis and anemia may predict MVP regimen response to advanced NSCLC.

关 键 词：药物疗法 非小细胞肺癌 丝裂霉素 长春酰胺 顺铂 疗效 

分 类 号：R734.2[医药卫生—肿瘤]